All In Biotech

Drug Trial Radar · NCT06386146

JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-30355 in Adult Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

144

Planned (sponsor's estimate)

Start

Jul 24, 2024

Primary completion

Jan 2027

Study completion Jul 2027

Sponsor

Sponsor type
Industry
First posted
Apr 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.

Conditions

  • Solid Tumors

Interventions

  • JAB-30355Drug

    Oral administration

  • JAB-30355Drug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity (DLT)Time frame: Approximately one year
  2. Number of participants with adverse eventsTime frame: Approximately three years

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site

    Denver, Colorado · Recruiting

  • Research site

    Lake Mary, Florida · Terminated

  • Research site

    St Louis, Missouri · Recruiting

  • Research site

    Canton, Ohio · Terminated

  • Research site

    Cleveland, Ohio · Recruiting

  • Research Site

    Nashville, Tennessee · Recruiting

  • Research site

    Houston, Texas · Recruiting

  • Research Site

    Beijing, Beijing Municipality, China · Recruiting

  • Research Site

    Beijing, Beijing Municipality, China · Recruiting

  • Research Site

    Beijing, Beijing Municipality, China · Recruiting

  • Research Site

    Guangzhou, Guangdong, China · Recruiting

  • Research Site

    Zhengzhou, Henan, China · Recruiting

  • Research Site

    Shenyang, Liaoning, China · Recruiting

  • Research Site

    Jinan, Shandong, China · Recruiting

  • Research Site

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.